All In Biotech

Drug Trial Radar · NCT02531126

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

877

Actual

Start

Dec 2, 2015

Primary completion

Dec 19, 2024

Study completion Dec 19, 2024

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible.

Conditions

  • Ulcerative Colitis

Interventions

  • RPC1063Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)Time frame: From first dose to 90 days post last dose (Up to approximately 92 months)

Locations

41 sites in 20 countries. Site status is shown where the registry gives one.

  • Local Institution - 144

    Tucson, Arizona

  • Local Institution - 102

    Anaheim, California

  • Local Institution - 117

    Mission Hills, California

  • Local Institution - 112

    Oak Lawn, Illinois

  • Local Institution - 119

    Baton Rouge, Louisiana

  • Local Institution - 127

    Jacksonville, North Carolina

  • Local Institution - 290

    Oklahoma City, Oklahoma

  • Local Institution - 143

    Portland, Oregon

  • Local Institution - 179

    Germantown, Tennessee

  • Local Institution - 122

    Dallas, Texas

  • Local Institution - 152

    Camperdown, New South Wales, Australia

  • Local Institution - 751

    Vitebsk, Belarus

  • Local Institution - 600

    Ghent, Belgium

  • Local Institution - 601

    Leuven, Belgium

  • Local Institution - 450

    Sofia, Bulgaria

  • Local Institution - 459

    Sofia, Bulgaria

  • Local Institution - 451

    Sofia, Bulgaria

  • Local Institution - 264

    Lindsay, Ontario, Canada

  • Local Institution - 611

    Osijek, Croatia

  • Local Institution - 342

    Klatovy, Czechia

  • Local Institution - 337

    Prague, Czechia

  • Local Institution - 535

    Berlin, Germany

  • Local Institution - 525

    Berlin, Germany

  • Local Institution - 545

    Frankfurt, Germany

  • Local Institution - 643

    Athens, Greece

  • Local Institution - 816

    Balatonfüred, Hungary

  • Local Institution - 808

    Debrecen, Hungary

  • Local Institution - 505

    Rehovot, Israel

  • Local Institution - 567

    Florence, Tuscany, Italy

  • Local Institution - 658

    Chisinau, Moldova

  • Local Institution - 659

    Chisinau, Moldova

  • Local Institution - 425

    Kłodzko, Poland

  • Local Institution - 677

    Bucharest, Romania

  • Local Institution - 673

    Bucharest, Romania

  • Local Institution - 910

    Bardejov, Slovakia

  • Local Institution - 364

    Seongnam-si, South Korea

  • Local Institution - 354

    Wŏnju, South Korea

  • Local Institution - 954

    Kharkiv, Ukraine

  • Local Institution - 957

    Vinnytsia, Ukraine

  • Local Institution - 243

    London, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.